Review of Biologics in Children With Rheumatic Diseases

Shabina Habibi; Athimalaipet V Ramanan


Int J Clin Rheumatol. 2012;7(1):81-93. 

In This Article


Rilonacept is an IL-1 R/IL1RacP/Fc fusion protein, which binds to soluble IL-1β, preventing it from binding to its receptor, having a longer half-life as compared with anakinra. Nine children with SOJIA were treated with rilonacept in the open-label phase of a randomized controlled, double-blind study.[39] ACR-Pedi 50 responses were impressive, with 55 and 78% attaining this at the end of 2 and 4 weeks, respectively. In those who had fever, an immediate disappearance of the fever was observed. Tolerability was acceptable. In the long-term open-label phase, outcomes at 24 months were recently presented.[40] Responses were sustained and therapy was generally well tolerated. However, two children developed MAS during therapy with rilonacept. A double-blind, randomized, placebo-controlled trial of rilonacept is ongoing.[102]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: